Conclusions
The authors conclude that individuals with SARS due to COVID‑19
requiring IMV have high mortality. In addition, an association of
mortality with an age of >60 years and the use of
azithromycin was observed.
References
- Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani
Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019
(COVID‑19): mechanism of action, detection and recent therapeutic
strategies. Virology . 2020;551: 1-9. doi:
10.1016/j.virol.2020.08.011
- Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et
al. Risk factors associated with mortality among patients with
COVID‑19 in intensive care units in Lombardy, Italy. JAMA Intern
Med . 2020;180(10): 1345-1355. doi:
10.1001/jamainternmed.2020.3539
- Grieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, et al.
Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on
days free of respiratory support in patients with COVID‑19 and
moderate to severe hypoxemic respiratory failure: the HENIVOT
randomized clinical trial. JAMA . 2021;325(17): 1731-1743. doi:
10.1001/jama.2021.4682
- Shang Y, Pan C, Yang X, Zhong M, Shang X, Wu Z, et al. Management of
critically ill patients with COVID‑19 in ICU: statement from frontline
intensive care experts in Wuhan, China. Ann Intensive Care .
2020;10(1): 73. doi:
10.1186/s13613-020-00689-1
- Amawi H, Abu Deiab GI, AA. AA, Dua K, Tambuwala MM. COVID‑19 pandemic:
an overview of epidemiology, pathogenesis, diagnostics and potential
vaccines and therapeutics. Ther Deliv . 2020;11(4): 245-268.
- Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al.
Asymptomatic carrier state, acute respiratory disease, and pneumonia
due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2):
facts and myths. J Microbiol Immunol Infect . 2020;53(3):
404-412. doi:
10.1016/j.jmii.2020.02.012
- Fauci AS, Longo DL, Hauser SL, et al. Harrison Medicina Interna. Rio
de Janeiro: McGrawHill, 2019; 20ª Edição, v.2.
- Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A,
et al. Case fatality rates for patients with COVID‑19 requiring
invasive mechanical ventilation. A meta-analysis. Am J Respir
Crit Care Med . 2021;203(1): 54-66. doi:
10.1164/rccm.202006-2405OC
- Greenland S, Daniel R, Pearce N. Outcome modelling strategies in
epidemiology: traditional methods and basic alternatives. Int J
Epidemiol . 2016;45(2): 565-575. doi:
10.1093/ije/dyw040
- Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation
study of the number of events per variable in logistic regression
analysis. J Clin Epidemiol . 1996;49(12): 1373-1379. doi:
10.1016/s0895-4356(96)00236-3
- Damayanthi HDWT, Prabani KIP, Weerasekara I. Factors associated for
mortality of older people with COVID 19: A systematic review and
meta-analysis. Gerontol Geriatr Med . 2021;7: 23337214211057392.
doi:
10.1177/23337214211057392
- Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C,
Wedderburn LR, et al. Male sex identified by global COVID‑19
meta-analysis as a risk factor for death and ITU admission. Nat
Commun . 2020;11(1): 6317. doi:
10.1038/s41467-020-19741-6
- Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al.
Effect of oral azithromycin vs placebo on COVID‑19 symptoms in
outpatients with SARS-CoV‑2 infection: A randomized clinical trial.JAMA . 2021;326(6): 490-498. doi:
10.1001/jama.2021.11517
- Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for
COVID‑19: living systematic review and network meta-analysis. Br J
Clin Pharmacol. 2020;370: m2980.
- Theoharides TC, Conti P. Dexamethasone for COVID‑19? Not so fast.J Biol Regul Homeost Agents . 2020;34(3): 1241-1243. doi:
10.23812/20-EDITORIAL_1-5
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M,
Bell JL, et al. Dexamethasone in hospitalized patients with COVID‑19.N Engl J Med . 2021;384(8): 693-704. doi:
10.1056/NEJMoa2021436
- Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D,
Migkou M, Tzanninis IG. et al. Emerging treatment strategies for
COVID‑19 infection. Clin Exp Med . 2021;21(2): 167-179. doi:
10.1007/s10238-020-00671-y
- Naime A, Bacha H, Tanni S. Uso de esteroides no tratamento da
COVID‑19. Projeto diretrizes. Associação Médica Brasileira .
2021.
- Guérin C, Reignier J, Richard JC. et al. Prone positioning in severe
acute respiratory distress syndrome. N Engl J Med. 2013;6;368(23):
2159-2168. doi:
10.1056/NEJMoa1214103
- Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V.
et al. Effect of prone positioning on the survival of patients with
acute respiratory failure. N Engl J Med . 2001;345(8): 568-573.
doi: 10.1056/NEJMoa010043
- Funakoshi K, Morita T, Kumanogoh A. Longer prehospitalization and
preintubation periods in intubated non-survivors and ECMO patients
with COVID‑19: A systematic review and meta-analysis. Front Med
(Lausanne ). 2021;8: 727101. doi:
10.3389/fmed.2021.727101
Figure
1. Study conduction flowchart according to the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
Table 1. Association between hospital death in patients with
severe acute respiratory syndrome owing to COVID-19 and sociodemographic
data, chronic diseases, lifestyle, and treatment (n = 397).